Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986488 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1A: BMS-986488 Monotherapy | EXPERIMENTAL | - |
| Part 1B: BMS-986488 + Adagrasib | EXPERIMENTAL | - |
| Part 1C: BMS-986488 + Adagrasib + Cetuximab | EXPERIMENTAL | - |
| Part 1D: BMS-986488 + Nivolumab | EXPERIMENTAL | - |
| Part 2A: BMS-986488 Monotherapy | EXPERIMENTAL | - |
| Part 2B: BMS-986488 + Adagrasib | EXPERIMENTAL | - |
| Part 2C: BMS-986488 + Adagrasib + Cetuximab | EXPERIMENTAL | - |
| Part 2D: BMS-986488 + Nivolumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986488 | DRUG | Specified dose on specified days |
| Adagrasib | DRUG | Specified dose on specified days |
| Cetuximab | DRUG | Specified dose on specified days |
| Nivolumab | DRUG | Specified dose on specified days |
Inclusion Criteria: * Participant must be ≥ 18 years of age. * Histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with any of the following tumor types:. * Part 1A: clear-cell renal cell carcinoma (ccRCC), clear-cell ovarian cancer (ccOC),...
BMS-986488 is an investigational small molecule being developed for the treatment of advanced malignant tumors. It is currently in Phase 1 clinical development, with a study evaluating it as a monotherapy and in combination therapy for participants with advanced malignant tumors.
BMS-986488 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting a Phase 1 clinical trial of the drug in participants with advanced malignant tumors.
BMS-986488 is in Phase 1 clinical development. It is an investigational drug, not yet approved, and is being studied in a single active trial for advanced malignant tumors. The trial is currently recruiting participants.
BMS-986488 is being studied in one Phase 1 clinical trial, NCT06764771, which is a study of BMS-986488 as monotherapy and combination therapy in participants with advanced malignant tumors. The trial is recruiting and has an enrollment of 437 participants.
BMS-986488 is the primary name for this investigational drug. No alternative names have been reported for it. It is a small molecule being studied in oncology for advanced malignant tumors.